Literature DB >> 9870137

Neurological aspects of adult phenylketonuria.

J Pietz1.   

Abstract

Phenylketonuria, an autosomal recessively transmitted disorder of amino acid metabolism, is caused by a deficiency of hepatic phenylalanine hydroxylase converting phenylalanine to tyrosine. Thus, phenylalanine accumulates to plasma levels exceeding 1200 mumol/l. Untreated phenylketonuria is characterized by microcephaly, epilepsy, severe mental retardation and, in some cases, progressive supranuclear motor disturbances. These symptoms can largely be prevented by the early start of a phenylalanine-restricted diet. Neurological investigations of treated patients reveal only minor neurological signs, such as tremor or brisk deep tendon reflexes. Magnetic resonance imaging shows white matter abnormalities. However, in single patients, progressive neurological symptoms occurred. Thus, the long-term prognosis of treated phenylketonuria is still under discussion.

Entities:  

Mesh:

Year:  1998        PMID: 9870137     DOI: 10.1097/00019052-199812000-00012

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  13 in total

Review 1.  Oxidative stress in phenylketonuria: what is the evidence?

Authors:  Graziela S Ribas; Angela Sitta; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2011-04-23       Impact factor: 5.046

2.  PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice.

Authors:  Jennifer E Embury; Catherine E Charron; Anatoly Martynyuk; Andreas G Zori; Bin Liu; Syed F Ali; Neil E Rowland; Philip J Laipis
Journal:  Brain Res       Date:  2006-11-15       Impact factor: 3.252

3.  Characterization of tremor in phenylketonuric patients.

Authors:  Belén Pérez-Dueñas; Josep Valls-Solé; Emilio Fernández-Alvarez; Jaon Conill; Maria Antonio Vilaseca; Rafael Artuch; Jaume Campistol
Journal:  J Neurol       Date:  2005-07-05       Impact factor: 4.849

4.  Diffusion-weighted imaging of white matter abnormalities in patients with phenylketonuria.

Authors:  M D Phillips; P McGraw; M J Lowe; V P Mathews; B E Hainline
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

5.  MR imaging-based volumetry in patients with early-treated phenylketonuria.

Authors:  Nadine H Pfaendner; Gitta Reuner; Joachim Pietz; Gregor Jost; Dietz Rating; Vincent A Magnotta; Alexander Mohr; Bodo Kress; Klaus Sartor; Stefan Hähnel
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

6.  Glutathione metabolism enzymes in brain and liver of hyperphenylalaninemic rats and the effect of lipoic acid treatment.

Authors:  Tarsila Barros Moraes; Giovana Reche Dalazen; Carlos Eduardo Jacques; Raylane Silva de Freitas; Andrea Pereira Rosa; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2014-02-02       Impact factor: 3.584

7.  Diffusion tensor images in children with early-treated, chronic, malignant phenylketonuric: correlation with intelligence assessment.

Authors:  Steven Shinn-Forng Peng; Wen-Yih Isaac Tseng; Yin-Hsiu Chien; Wuh-Liang Hwu; Hon-Man Liu
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

8.  Phenylalanine induces oxidative stress and decreases the viability of rat astrocytes: possible relevance for the pathophysiology of neurodegeneration in phenylketonuria.

Authors:  Thales Preissler; Ivi Juliana Bristot; Bruna May Lopes Costa; Elissa Kerli Fernandes; Elenara Rieger; Vanessa Trindade Bortoluzzi; Itiane Diehl de Franceschi; Carlos Severo Dutra-Filho; José Claudio Fonseca Moreira; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2015-11-16       Impact factor: 3.584

9.  The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study.

Authors:  B K Burton; D K Grange; A Milanowski; G Vockley; F Feillet; E A Crombez; V Abadie; C O Harding; S Cederbaum; D Dobbelaere; A Smith; A Dorenbaum
Journal:  J Inherit Metab Dis       Date:  2007-09-12       Impact factor: 4.982

10.  Protective effect of recombinant adeno-associated virus 2/8-mediated gene therapy from the maternal hyperphenylalaninemia in offsprings of a mouse model of phenylketonuria.

Authors:  Sung-Chul Jung; Joo-Won Park; Hyun-Jeong Oh; Jin-Ok Choi; Kyung-In Seo; Eun-Sook Park; Hae-Young Park
Journal:  J Korean Med Sci       Date:  2008-10       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.